Opportunity ID: 171553

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-12-505
Funding Opportunity Title: Limited Competition for the Continuation of the Halt-Polycystic Kidney Disease Trials Data Coordinating Center (DCC) (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 18, 2012
Last Updated Date:
Original Closing Date for Applications: Jul 30, 2012
Current Closing Date for Applications: Jul 30, 2012
Archive Date: Aug 30, 2012
Estimated Total Program Funding: $1,200,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following:
As this FOA is a limited competition opportunity, only the institution that is the principal employer of the Program Director(s)/Principal Investigator(s) of the HALT Data Coordinating Center is eligible to apply to this FOA.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this limited competition is to extend the
activities of the Data Coordinating Center (DCC) during the final two years
of patient follow-up of the two ongoing HALT-Polycystic Kidney Disease (PKD)
clinical trials.  The extension will insure the statistical power and
significance of the study outcomes.  The HALT-PKD Trials are comprised of two
studies (A & B) that are both fully enrolled.  HALT-PKD Study A is
evaluating the impact of renin-angiotensin-aldosterone system (RAAS) blockade
on progression of disease in 548 hypertensive PKD patients with estimated
glomerular filtration rate (GFR) > 60ml/min/1.73 m2. The primary endpoint
of the study is the percent change in total kidney volume, as measured by
magnetic resonance imaging (MRI) over time.  HALT-PKD Study B is evaluating
the impact of RAAS blockade on progression of disease in 472 hypertensive PKD
patients with estimated GFR 30-60 ml/min/1.73 m2. The primary endpoint of
Study B is a composite endpoint of time to the 50% reduction of baseline
estimated GFR, ESRD (initiation of dialysis or preemptive transplant), or death.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-12-505.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
93.847 ADOBE-FORMS-B2 ADOBE-FORMS-B2 PKG00122610 Jun 30, 2012 Jul 30, 2012 View

Package 1

Mandatory forms

171553 RR_SF424_1_2-1.2.pdf

171553 PerformanceSite_1_4-1.4.pdf

171553 RR_OtherProjectInfo_1_3-1.3.pdf

171553 RR_KeyPersonExpanded_1_2-1.2.pdf

171553 PHS398_CoverPageSupplement_1_4-1.4.pdf

171553 PHS398_ResearchPlan_1_3-1.3.pdf

171553 PHS398_Checklist_1_3-1.3.pdf

Optional forms

171553 RR_SubawardBudget30-1.2.pdf

171553 PHS398_ModularBudget_1_2-1.2.pdf

171553 RR_Budget-1.1.pdf

171553 PHS_CoverLetter_1_2-1.2.pdf

2025-07-10T16:06:30-05:00

Share This Post, Choose Your Platform!

About the Author: